Article:
Newman, J., Varian, F., Hitchcock, F. et al. (2025) Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension. European Respiratory Journal, 65 (6). 2500198. ISSN: 0903-1936

https://doi.org/10.1183/13993003.00198-2025

EUROPEAN RESPIRATORY *journal*

FLAGSHIP SCIENTIFIC JOURNAL OF ERS

Early View

Research Letter

Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension

Joseph Newman, Frances Varian, Felicity Hitchcock, Rebecca Burney, Gregg Harry Rawlings, John Harrington, Ze Ming Goh, Jenna Ablott, David G Kiely, Iain Armstrong, A. A. Roger Thompson, Jill Carlton, Elin Haf Davies, Alexander Rothman, Mark Toshner

Please cite this article as: Newman J, Varian F, Hitchcock F, *et al*. Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension. *Eur Respir J* 2025; in press (https://doi.org/10.1183/13993003.00198-2025).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Comparability, acceptability and longitudinal adherence with digital emPHasis-10 in pulmonary arterial hypertension

Joseph Newman,*[1,2] Frances Varian,*[3,4] Felicity Hitchcock,[3,4] Rebecca Burney,[3,4] Gregg Harry Rawlings,[5] John Harrington,[4] Ze Ming Goh,[3,4] Jenna Ablott,[4] David G Kiely,[3,4] Iain Armstrong,[3,4,6] A. A. Roger Thompson,[3,4] Jill Carlton,[7] Elin Haf Davies,[8] National Cohort Study of Pulmonary Hypertension Collaboration, UniPHy Clinical Trials Network, Alexander Rothman,[#3,4] Mark Toshner[#1,2]

1. Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, UK
2. Royal Papworth Hospital, Papworth Rd, Trumpington, Cambridge, UK
3. Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, UK
4. Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, UK
5. Clinical and Applied Psychology Unit, University of Sheffield, UK
6. Pulmonary Hypertension Association United Kingdom, Sheffield, UK
7. Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, UK
8. Aparito Ltd., Wrexham, UK

*Joint first authors

[#]Joint last authors

Corresponding author: Joseph Newman

Address: Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, UK, CB2 0BB

Email: joseph.newman@nhs.net

Word limit: 1169/1200

Figures: 1

References: 20

To the Editor:

Pulmonary hypertension (PH) affects 1% of the global population and significantly impacts health-related quality of life (HRQoL).[1,2] Patient reported outcome measures (PROMs) are standardised tools used in clinical practice and research to assess health outcomes from the patient's perspective. Routine measurement of HRQoL is supported by clinical guidelines, recommending disease-specific PROMs.[1] EmPHasis-10 is a widely used ten-item PROM developed for patients in any World Health Organisation (WHO) PH group.[2,3] Available in numerous languages, it has strengths in both its psychometric properties and feasibility.[2,4] However, it is currently only available in a paper-based format.

Electronic PROMs (ePROMs), such as those delivered on smartphone applications (apps), are recommended by international stakeholders and regulatory bodies.[5-8] Advantages include improved data integrity and accuracy, facilitation and tracking of 'skip' patterns, high acceptability, better compliance, increased power leading to smaller sample sizes, and easier processing.[9] The capacity for patients to use their own devices and the ubiquity of smartphones could reduce trial delivery costs whilst maintaining equitable access. Offering a choice of PROM formats is expected to enhance inclusion and engagement.[8,10,11]

International guidelines recommend evaluation of alternative PROM formats to ensure that measurement properties do not change and only recommend full psychometric validation where certain criteria are met.[8,9] We report the first study evaluating digital and paper emPHasis-10 equivalence, longitudinal adherence and acceptability from the patients' perspective.

As part of a United Kingdom (UK) multi-centre prospective observational study, adult patients with pulmonary arterial hypertension (PAH) consented to participate in Cohort-Digital (IRAS 123349, REC 13/EE/0203) and/or Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Pulmonary Hypertension (FIT-PH, NCT04078243, REC 19/YH/0354). Participants completed the paper-based emPHasis-10 and the digital format via the Atom5™ app (iOS or Android) as a "bring your own device" study.[12] Participants received fortnightly pre-programmed push notifications (alerts) for a 26-week period asking them to remotely complete the digital emPHasis-10. Passive compliance was audited, with no additional active adherence interventions deployed. Patients could contact the study team for technical assistance if required, and although not audited systematically, this was rare.

A predominantly prevalent and stable PAH population was prioritised. International PROM development guidelines recommend a minimum sample size of fifty for evaluation of measurement error[13]. Stability was determined by a patient-reported neutral score (-1, 0 or +1) on a digital subjective global anchor rating scale (-3 to +3)

asking "*with respect to your pulmonary hypertension, how would you describe yourself NOW compared to when you last completed this questionnaire?*". The UTAUT (Unified Theory of Acceptance and Use of Technology) underpinned a digital survey to evaluate themes of usability and acceptability.[14]

Digital emPHasis-10 was developed and tested with focus groups of patients with PH in collaboration with Pulmonary Hypertension Association UK. Following international recommendations, full psychometric evaluation was not required as the format change from paper to digital was mild to moderate.[9] These 'non-substantive' formatting differences included (a) change in instructions from "placing a tick" (boxes) to "selecting the number" (Likert scale) (b) change from ten items on a single sheet to one item per screen (c) no total score immediately visible on the digital version and (d) automated date and time stamping of digital completion.

Fifty-one patients were enrolled: median age 53 years (IQR 41-62), 71% female, 81% white. Most (41/51; 80%) had a diagnosis of idiopathic PAH and the median time since diagnosis was 5 years (IQR 1-11.5). 82% of patients had a low/intermediate-low COMPERA 2.0 risk score with WHO Functional Class I/II/III/ IV as 7/41/50/ 2%. respectively. The cohort was geographically diverse, with patients enrolled from across the UK.

Fifty-seven pairs of digital/paper PROMs (from multiple clinic visits) were available for evaluation from stable patients. Median time between digital and paper completion was +1 day (IQR 0 to 5) with a range of up to 31 days between formats where patients reported no significant change in their HRQoL as evaluated using the patient-reported anchor score. Paired samples from two participants were excluded after reporting they completed the digital format incorrectly, accidentally inverting the scales. Samples where patients reported a change in HRQoL on the global anchor scale were not included for equivalence comparison.

Mean scores were equal at 20/50 (±14) with standard error of measurement (SEM) of 2. Scores were consistent between paper and digital formats (Spearman's r=0.98, $p<0.0001$, Cronbach's alpha 0.99). Bland Altman analysis (n=57) showed a bias (systematic error) of 0.15 (SD 2.3) with 95% limits of agreement from -4.7 to 4.4 (Figure 1A). All random variation fell below the thresholds estimated to be the MCID (Figure 1A).[15,16]

The overall adherence (Cohort Digital n=49) to completing fortnightly ePROMs was a median of 79% (IQR 29% to 100%) and 29% (14/49) of patients achieved 100% compliance. This included one participant who withdrew from the study before accessing the app. There was a steady drop-off in completion during the first six weeks of the study before reaching a plateau of 61% by 26 weeks (Figure 1B).

Patient-reported acceptability of the app-based emPHasis-10 was high (Figure 1C), consistent with other studies showing preferences for ePROMs[17]. Most participants reported finding it useful, usable, preferable and would use it again in clinical practice or research if available, without major barriers to adoption.

The primary finding from this study is that patients responded consistently between paper and digital formats of emPHasis-10. A further strength is the consistency of PROM scores with patient-reported stability, highlighting the value of anchor-based methodology. Based on the strong association, consistency and acceptability metrics, we suggest that paper or digital formats can be selected in accordance with patient preference, trial design or clinical setting.

The small SEM (score of 2) of digital emPHasis-10 during a period of self-reported stability suggests that a threshold of >2 could be significant. Low scoring variability suggests that emPHasis-10 may be sensitive to changes below the registry-estimated MCIDs of 6 to 8[15,16]. Evaluation of responsiveness of digital emPHasis-10 is underway through on-going therapeutic trials.[18,19]

Most patients regularly used the ePROM. The observed drop-off over six months is a recognised phenomenon.[17] The modest initial disengagement could be mitigated by making the tool seemingly more interactive or useful, such as diarising ePROM scores over time - a function we have subsequently co-developed with patients. This tracker function also aims to reassure patients that data is not lost, a concern expressed on the UTAUT survey. An “investigator in the loop” design, rather than solely notification-driven reminders, is recommended to maximise completion rates, address technical issues and prevent drop-off, as supported by our usability data and the literature[20]. Strategies to optimise longitudinal adherence are ongoing through the Cohort-Digital randomised study.

In conclusion, this is the first equivalence evaluation of a digital format of emPHasis-10. Established using a patient-reported anchor question, this methodology follows international recommendations and strengthens the field in HRQoL outcome measurement, with broad applicability. This ePROM is highly acceptable to patients with PAH and has reasonable adherence longer-term. The digital format will allow for more frequent, convenient and remote collection of meaningful HRQoL data in both clinical practice and trials.

Acknowledgements

Thank you to Pulmonary Hypertension Association United Kingdom (PHA UK) and patient representatives for supporting the design and evaluation of the digital emPHasis-10 and to Aparito Ltd for the technical development of the ePROM and its use in the clinical research study. Thank you to the patients who participated in this research study. Thank you to the British Heart Foundation for funding this research.

Declarations of interest

Professor DG Kiely and Dr I Armstrong were involved in the derivation of EmPHasis-10. EHD is an employee of Aparito Ltd. These authors contributed to reviewing the manuscript, but statistical analysis was performed independently by JN/FV. Other authors have no conflicts of interest.

Funding

Wellcome Trust Clinical Research Career Development Fellowship (AMKR: 206632/Z/17/Z), BHF Intermediate Fellowship (AART: FS/18/13/33281), MRC Experimental Medicine grant (AMKR/MT/DGK: MR/W026279/1), BHF Clinical Research Training Fellowship (HZ/AMKR: FS/CRTF/23/24465, MT/JN: FS/CRTF/22/24390), EPSRC Project Grant (AMKR: EP/Z531297/1). The research was carried out at the National Institute for Health and Care Research (NIHR) Sheffield and Cambridge cardiorespiratory Biomedical Research Centres. AR is grateful to Richard Hughes, whose generous philanthropic support has helped to make this work possible.

Disclosures

AART research funding: Heart Research UK, Janssen-Cilang Ltd, British Heart Foundation, and honoraria from Janssen-Cilad ltd for lectures and education. **AMKR**: research funding: Wellcome Trust Clinical Research Career Development Fellowship (206632/Z/17/Z),), EPSRC Project Grant (AMKR: EP/Z531297/1), Medical Research Council (UK) Experimental Medicine Award (MR/W026279/1), BHF Clinical Research Training Fellowship (HZ/AMKR: FS/CRTF/23/24465), NIHR Biomedical Research Centre Sheffield, Contribution in kind: Medtronic Inc., Abbott Laboratories, Endotronix Inc., Novartis, Janssen, Merk. Research support and consulting: NXT Biomedical, Endotronix Inc., SoniVie, Neptune, Gradient. **DGK** has received personal funding from the NIHR Biomedical Research Centre Sheffield, research funding from Ferrer, GSK and Janssen and consulting and educational funding from Acceleron, Altivant, Ferrer, Gossamer, Janssen, MSD and United Therapeutics. **FV** has received educational funding from Janssen and is a Medical Research Council (UK) clinical fellow. **JN** Research funding: British Heart Foundation. Education and travel funding: Aparito Ltd and United Therapeutics. **MT**: Research funding: NIHR Biomedical Research Centre Cambridge, NIHR HTA. Personal support: GSK and Jansen. All others: none.

References

1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023 Jan 6;61(1):2200879.

2. Varian F, Burney R, Pearson C, Goh ZM, Newman J, Rawlings G, Zafar H, Kiely DG, Thompson RAA, Condliffe R, Toshner M, McCormack C, Armstrong I, Peasgood T, Carlton J. Rothman A. Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework. (In-press European Respiratory Review, pre-print available from: https://www.medrxiv.org/content/10.1101/2024.08.09.24311740v2.full)

3. Yorke J, Corris P, Gaine S, Gibbs JSR, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. European Respiratory Journal. 2014 Apr 1;43(4):1106–13.

4. Rose SW, Highland KB, Kelkar AA. Clinical Utility of Patient-Reported Outcome Instruments in the Management of Pulmonary Hypertension: A Systematic Review. JACC Heart Fail. 2024 Feb;12(2):366-376.

5. Aiyegbusi OL, Davies EH, Myles P, Williams T, Frost C, Haroon S, et al. Digitally enabled decentralised research: opportunities to improve the efficiency of clinical trials and observational studies. BMJ Evid Based Med. 2023 Feb 21;bmjebm-2023-112253.

6. WHO. WHO recommendations on digital interventions [Internet]. [cited 2023 Aug 15]. Available from: https://www.who.int/publications/i/item/9789241550505

7. Rosa C, Marsch LA, Winstanley EL, Brunner M, Campbell ANC. Using digital technologies in clinical trials: Current and future applications. Contemp Clin Trials. 2021 Jan;100:106219.

8. FDA, CDER. CENTER FOR DRUG EVALUATION AND RESEARCH INNOVATION PREDICTABILITY ACCESS Framework for the Use of Digital Health Technologies in Drug and Biological Product Development Framework for the Use of Digital Health Technologies in Drug and Biological Product Development [Internet]. 2023. Available from: https://www.fda.gov/media/151712/download.

9. O'Donohoe P, Reasner DS, Kovacs SM, Byrom B, Eremenco S, Barsdorf AI, et al. Updated Recommendations on Evidence Needed to Support Measurement Comparability Among Modes of Data Collection for Patient-Reported Outcome Measures: A Good Practices Report of an ISPOR Task Force. Value in Health. 2023 May;26(5):623–33.

10. NHS. NHS: what is digital inclusion [Internet]. [cited 2023 Aug 15]. Available from: https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/digital-inclusion/what-digital-inclusion-is

11. Tan RKJ, Wu D, Day S, Zhao Y, Larson HJ, Sylvia S, et al. Digital approaches to enhancing community engagement in clinical trials. NPJ Digit Med. 2022 Mar 25;5(1):37.

12. Critical Path Institute. Electronic Clinical Outcome Assessment Consortium. Available from: https://c-path.org/program/electronic-clinical-outcome-assessment-consortium/

13. Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, et al. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. Health Qual Life Outcomes. 2024 Jul 9;22(1):48. Study design checklist is available online from: https://www.cosmin.nl/wp-content/uploads/COSMIN-study-designing-checklist_final.pdf [accessed March 2025]

14. Venkatesh V, Morris MG, Davis GB, Davis FD. User Acceptance of Information Technology: Toward a Unified View. 2003. *MIS Quarterly*. **27** (3): 425–478.

15. Hendriks PM, van Thor MCJ, Wapenaar M, Chandoesing P, van den Toorn LM, van den Bosch AE, et al. The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Med. 2021 Sep 1;186:106525.

16. Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT; PHAR Study Group. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J. 2021 Feb 25;57(2):2000414.

17. Meirte J, Hellemans N, Anthonissen M, Denteneer L, Maertens K, Moortgat P, Van Daele U. Benefits and Disadvantages of Electronic Patient-reported Outcome Measures: Systematic Review. JMIR Perioper Med. 2020 Apr 3;3(1):e15588.

18. Varian F, Dick J, Battersby C, Roman S, Ablott J, Watson L, et al. Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies. Pulm Circ. 2024 Jan 17;14(1).

19. Deliu N, Das R, May A, Newman J, Steele J, Duckworth M, Jones RJ, Wilkins MR, Toshner MR, Villar SS. StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2. Trials. 2024 Oct 15;25(1):680

20. Tackney MS, Steele A, Newman J, Fritzsche MC, Lucivero F, Khadjesari Z, Lynch J, Abbott RA, Barber VS, Carpenter JR, Copsey B, Davies EH, Dixon WG, Fox L, González J, Griffiths J, Hinchliffe CHL, Kolanko MA, McGagh D, Rodriguez A, Roussos G, So KBE, Stanton L, Toshner M, Varian F, Williamson PR, Yimer BB, Villar SS. Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event. Trials. 2024 Aug 3;25(1):521.



Figure 1